Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
KALA Stock Forecast 2026-2027
$2.06
Current Price
$38.30M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to KALA Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
KALA Price Momentum
-7.6%
1 Week Change
-50.4%
1 Month Change
-99.0%
1 Year Change
-92.6%
Year-to-Date Change
-99.8%
From 52W High of $1,030.00
+1.5%
From 52W Low of $2.03
📊 TOP ANALYST CALLS
Did KALA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Kala Pharmaceuticals is one of their latest high-conviction picks.
Latest KALA Stock Price Targets & Analyst Predictions
KALA has shown a year-to-date change of -92.6% and a 1-year change of -99.0%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for KALA. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KALA Analyst Ratings
0
Buy
1
Hold
0
Sell
KALA Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $2.06
Latest KALA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KALA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 29, 2025 | HC Wainwright & Co. | Yi Chen | Neutral | Downgrade | $N/A |
| Sep 17, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Sep 11, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Sep 8, 2025 | Mizuho | Outperform | Initiates | $N/A | |
| Jul 11, 2025 | Ladenburg Thalmann | Buy | Initiates | $N/A | |
| Jun 2, 2025 | Oppenheimer | Andreas Argyrides | Outperform | Assumes | $15.00 |
| May 23, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Apr 4, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 13, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 15, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 19, 2024 | Oppenheimer | Outperform | Reiterates | $N/A | |
| May 17, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Apr 2, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Apr 1, 2024 | Oppenheimer | Outperform | Reiterates | $N/A | |
| Nov 17, 2023 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 11, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 10, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 1, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 12, 2023 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 27, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A |
Kala Pharmaceuticals, Inc. (KALA) Competitors
The following stocks are similar to Kala Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
KALA
Kala Pharmaceuticals
mkt cap
38.30M
Kala Pharmaceuticals, Inc. (KALA) Financial Data
Kala Pharmaceuticals, Inc. has a market capitalization of $38.30M with a P/E ratio of 11.4x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -238.7%.
Valuation Metrics
Market Cap
$38.30M
Enterprise Value
$29.53M
P/E Ratio
11.4x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+22.9%
Current Ratio
7.9x
Debt/Equity
0.0x
ROE
-238.7%
ROA
-69.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Kala Pharmaceuticals, Inc. (KALA) Business Model
About Kala Pharmaceuticals, Inc.
What They Do
Develops therapeutics for rare eye diseases.
Business Model
Kala Pharmaceuticals operates as a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for rare and severe eye diseases. The company generates revenue through its research and clinical trials, including its lead candidate KPI-012, and has recently ventured into AI solutions for biotech research, which may open new revenue streams.
Additional Information
Kala Pharmaceuticals utilizes proprietary nanoparticle technology and is exploring preclinical programs for inherited retinal diseases. The company has also entered into a strategic partnership to leverage AI in its drug development processes, indicating a forward-looking approach to enhance efficiency and outcomes in biotechnology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
38
CEO
Mr. David Elliot Lazar
Country
United States
IPO Year
2017
Website
www.kalarx.comKala Pharmaceuticals, Inc. (KALA) Latest News & Analysis
Latest News
KALA BIO Announces Reverse Stock Split
1 month ago
Quick Summary
KALA BIO, Inc. plans a reverse stock split at a ratio of 1-for-50 for its common stock, effective May 07, 2026.
Why It Matters
KALA BIO's reverse stock split may impact share liquidity and perception of financial health, potentially affecting stock price and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
KALA Bio, Inc. (NASDAQ: KALA) announced the celebration of a significant Executive Order signed by President Donald J. Trump on April 21, 2026.
Why It Matters
The Executive Order may impact KALA BIO's operations, potentially influencing regulatory environment and funding opportunities, affecting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
KALA's engagement will review its clinical assets, development options, and AI-driven opportunities, particularly focusing on the MSC Secretome platform.
Why It Matters
KALA's assessment of clinical assets and AI opportunities could enhance its growth potential and innovation, impacting future revenue and stock value positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The company announced that BIRA is now operational in client-controlled environments, signaling its entry into the revenue-generating AI infrastructure market.
Why It Matters
BIRA's launch in client-controlled environments signals a new revenue stream, potentially enhancing the company's growth prospects and attracting investor interest in AI infrastructure.
Source: Benzinga
Market Sentiment:
Positive
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live
2 months ago
Quick Summary
A Next-Generation Agentic AI Platform has been deployed for global biotech and pharmaceutical firms, offering secure and scalable autonomous research solutions.
Why It Matters
The deployment of this AI platform indicates potential growth in biotech and pharma sectors, promising enhanced efficiency and innovation, which could drive stock prices and investment opportunities.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Red Light Holland Corp. has partnered with Kala Bio to utilize its AI platform for the clinical development of the psilocybin drug candidate PEX010, licensed from Younet.
Why It Matters
The deployment of AI for PEX010's clinical development could enhance efficiency and reduce costs, potentially accelerating drug approval timelines and impacting stock performance for involved companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About KALA Stock
What is Kala Pharmaceuticals, Inc.'s (KALA) stock forecast for 2026?
Analyst forecasts for Kala Pharmaceuticals, Inc. (KALA) are not currently available. The stock is trading at $2.06.
Is KALA stock a good investment in 2026?
According to current analyst ratings, KALA has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.06. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for KALA stock?
Price predictions from Wall Street analysts for KALA are not currently available. The stock is trading at $2.06.
What is Kala Pharmaceuticals, Inc.'s business model?
Kala Pharmaceuticals operates as a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for rare and severe eye diseases. The company generates revenue through its research and clinical trials, including its lead candidate KPI-012, and has recently ventured into AI solutions for biotech research, which may open new revenue streams.
What is the highest forecasted price for KALA Kala Pharmaceuticals, Inc.?
Price targets from Wall Street analysts for KALA are not currently available. The stock is trading at $2.06.
What is the lowest forecasted price for KALA Kala Pharmaceuticals, Inc.?
Price targets from Wall Street analysts for KALA are not currently available. The stock is trading at $2.06.
What is the overall KALA consensus from analysts for Kala Pharmaceuticals, Inc.?
The overall analyst consensus for KALA is neutral. Out of 9 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are KALA stock price projections?
Stock price projections, including those for Kala Pharmaceuticals, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 7, 2026 3:52 PM UTC